XENE Xenon Pharmaceuticals Forecast, Technical & Fundamental Analysis
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders... Show more
XENE is expected to report earnings to fall 2.56% to -113 cents per share on August 12
Q2'26
Est.
$-1.14
Q1'26
Beat
by $0.01
Q4'25
Missed
by $0.12
Q3'25
Est.
$-1.15
Q2'25
Beat
by $2.06
The last earnings report on May 07 showed earnings per share of -116 cents, beating the estimate of -117 cents. With 929.96K shares outstanding, the current market capitalization sits at 6.55B.
A.I. Advisor
published General Information
General Information
a provider of drug discovery and development services
A.I.dvisor indicates that over the last year, XENE has been loosely correlated with RLMD. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then RLMD could also see price increases.
Aroon Indicator for XENE shows an upward move is likely
XENE's Aroon Indicator triggered a bullish signal on July 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 188 similar instances where the Aroon Indicator showed a similar pattern. In of the 188 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on XENE as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for XENE just turned positive on June 17, 2026. Looking at past instances where XENE's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
XENE moved above its 50-day moving average on June 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for XENE crossed bullishly above the 50-day moving average on June 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
XENE broke above its upper Bollinger Band on July 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XENE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.895) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). XENE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (588.235) is also within normal values, averaging (434.181).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
